Highest-materiality recent filing
FDA agreed to revised ORIGIN 3 eGFR analysis plan to support potential full approval of atacicept in IgA Nephropathy.
Vera Therapeutics stockholders elect three Class II directors, ratify KPMG, approve say-on-pay
Michael M. Morrisey elected with 45.3M For, 13.8M Withheld; Patrick G. Enright with 54.7M For; James R. Meyers with 58.9M For.
Vera Therapeutics Q1 net loss widens to $1.69/shr; atacicept gets priority review with PDUFA July 7
Net loss of $121.0M in Q1 2026 vs $51.7M in Q1 2025; diluted EPS loss of $1.69 vs $0.81.
Vera Therapeutics appoints Christopher Hite to Board of Directors
Christopher Hite appointed as Class III Director effective March 5, 2026.
Net loss of $299.6M (diluted EPS -$4.66), vs $152.1M loss in FY 2024.
Vera Therapeutics Announces Departure of Chief Legal Officer Jason Carter
Jason Carter will cease to be Chief Legal Officer of Vera Therapeutics, effective December 24, 2025.
Vera Therapeutics prices public offering of 6.14M shares at $42.50, raising ~$260.9M
Entered underwriting agreement Dec 9 to sell 6,138,108 shares of common stock at $42.50/share.
Vera Therapeutics appoints James R. Meyers to Board of Directors
James R. Meyers appointed as Class II Director effective Nov 25, 2025; term expires at 2026 annual meeting.
Atacicept achieved 46% reduction from baseline in UPCR at week 36; 42% reduction vs placebo (p<0.0001).
Vera Therapeutics Q3 net loss $80.3M; atacicept BLA submission on track for Q4 2025
Net loss $80.3M ($1.26/sh) vs $46.6M ($0.85) in Q3 2024; cash & securities $497.4M.
Vera Therapeutics Q2 net loss $76.5M; on track to submit atacicept BLA in Q4 2025
Net loss $76.5M ($1.20 per share) vs $33.7M ($0.62) year-over-year; cash $556.8M as of June 30, 2025.
Vera Therapeutics enters $200M at-the-market equity offering agreement with TD Cowen
New Sales Agreement with TD Cowen to sell up to $200M of Class A common stock from time to time.
Vera Therapeutics enters up to $500M loan facility with Oxford Finance; $75M initial draw
Initial $75M funded June 4, 2025; remaining $50M from $125M first tranche drawable in 2026.
Vera Therapeutics atacicept Phase 3 IgAN trial meets primary endpoint; 46% proteinuria reduction
Atacicept achieved 46% reduction from baseline in UPCR, 42% vs placebo (p<0.0001) at week 36.
Elected three Class I directors (Fordyce, Seidenberg, Hall) each with >49M votes for, ~5.4M withheld, and 1.8M broker non-votes.
Vera Therapeutics Q1 net loss $51.7M; on track for Phase 3 atacicept results in 2Q 2025
Net loss of $51.7M ($0.81/share) vs $28.4M ($0.56/share) same quarter last year.
Vera Therapeutics reports 2024 net loss $152.1M; atacicept Phase 3 primary endpoint due Q2 2025
Net loss of $152.1M ($2.75 diluted EPS) vs $96.0M ($2.25) in 2023; cash burn $134.7M operating.
Vera Therapeutics releases corporate presentation at J.P. Morgan Healthcare Conference
Updated corporate presentation furnished as Exhibit 99.1, available on company website.
Vera Therapeutics reports Q3 net loss $46.6M, raises $345M; atacicept Ph3 enrollment done
Net loss of $46.6M ($0.85/shr) vs $20.1M ($0.45) in Q3 2023; cash $353.3M as of Sept 30.
Vera Therapeutics launches $300M public offering of 7.1M shares at $42.00
7,142,858 shares offered at $42.00/share; gross proceeds ~$300M before discounts and expenses.
Vera Therapeutics reports positive 96-week ORIGIN Phase 2b data for atacicept in IgAN; cash ~$353M
Atacicept showed -66% Gd-IgA1 reduction, 75% hematuria resolution, -52% proteinuria reduction over 96 weeks.
Vera expands atacicept program to broader IgAN and autoimmune kidney diseases with two new studies
ORIGIN Extend to start Q4 2024, providing extended atacicept access and long-term data for ORIGIN participants.
Net loss $33.7M ($0.62/diluted share) vs $20.2M ($0.46) in Q2 2023; cash $384.4M sufficient through approval and US launch.
Appoints David Johnson as COO effective July 1, 2024
David Johnson named COO; previously Chief Commercial Officer at Global Blood Therapeutics.
Vera Therapeutics appoints Christy Oliger to board; grants 25K share options
Christy Oliger appointed as Class III Director effective June 7, 2024, term through 2027 annual meeting.
Vera Therapeutics stockholders re-elect two Class III directors; ratify KPMG as auditor
Andrew Cheng re-elected with 27.4M votes for, 13.0M withheld; Scott Morrison with 31.6M for, 8.8M withheld.
Vera Therapeutics Q1 net loss $28.4M; cash $403.7M; Phase 3 enrollment on track
Net loss of $28.4M ($0.56 diluted EPS) vs $30.1M ($0.80) in Q1 2023.
On July 1, 2024, Vera Therapeutics, Inc. (the “ Company ”) announced the appointment of David Johnson as the Company’s Chief Operating Officer, effective July 1, 2024
On June 7, 2024, the board of directors (the “Board”) of Vera Therapeutics, Inc. (the “Company”) appointed Christy Oliger to the Board, effective immediately.
Max materiality 0.95 · Median 0.70 · Most common event other_material